8 **PSYCHIATRIC TIMES**

www.psychiatrictimes.com

INTEGRATIVE MEDICINE

Integrative Management of ADHD: What the Evidence Suggests

t is important for mental health professionals to be familiar with emerging research findings about widely used complementary and alternative medicine (CAM) treatments of attention-deficit/hyperactivity disorder (ADHD) in order to provide patients with accurate information on efficacy, safety, and appropriate use.

A high percentage of children and adults who have been given a diagnosis of ADHD use alternative therapies alone or in combination with conventional pharmacological treatment.¹ More than half of parents of children with ADHD treat their children's symptoms using 1 or more CAM therapies, most commonly vitamins, dietary changes, and expressive therapies; yet only about 10% disclose use of such nonpharmacological therapies to their child's pediatrician.² Most nonpharmacological therapies used to treat ADHD are supported by limited evidence; however, as many as 80% of patients who use herbal preparations and other natural products regard these therapies as the primary treatment of their symptoms.²

Conventional treatment

Stimulant medications, including dextroamphetamine, methylphenidate, and related compounds, are the most widely used treatments of ADHD. The nonstimulant atomoxetine has less potential for abuse but also may be less effective than stimulants.³ SSRIs and other antidepressants are used with varying degrees of success. Behavioral modification aimed at rewarding desirable behavior and extinguishing disruptive or inappropriate behavior continues to be a mainstay of conventional treatment. Psychotherapy and psychosocial support help reduce anxiety and feelings of loss of control that frequently accompany ADHD. It is estimated that ADHD is correctly diagnosed and treated in fewer than one-fifth of adults, which results in significant social and occupational morbidity.

Limitations and risks of conventional treatment

Long-term amphetamine use in childhood is associated with delays in normal development.⁴ One-third of individuals of all ages who take stimulants for ADHD report significant adverse effects, including insomnia, decreased appetite, and abdominal pain.5 Cases of stimulant-induced psychosis have also been reported.6 Stimulants and other conventional treatments of ADHD in adults are probably only half as effective as they are in children.4

Adverse effects of nonstimulant drugs used to treat ADHD include hypertension, decreased appetite, nausea, fatigue, liver toxicity, insomnia, and seizures. A meta-analysis of 6 controlled trials concluded that stimulant therapy started in childhood reduces the risk of subsequent substance abuse by as much as one-half. In contrast, stimulants started in adolescence or adulthood increase the risk of future substance abuse.7 Nonstimulant medications and extendedrelease stimulants are less likely to be abused.8

Nonconventional therapies

Dietary changes. Early studies on a highly restrictive diet that eliminates all processed foods reported promising findings in children with ADHD9; however, a review of controlled studies failed to support these findings.¹⁰ The oligoantigenic diet (OAD) is a highly restrictive elimination diet in which food colorings and additives as well as dairy products, sugar, wheat, corn, citrus, eggs, soy, yeast, nuts, and chocolate are eliminated. Numerous studies on the OAD reported significant reductions in hyperactivity in children with ADHD when specific food items were eliminated from the diet using an open-label protocol.¹¹ In most studies, symptoms recurred when children were subsequently challenged with the eliminated food item following a placebo-controlled protocol. The significance of findings on elimination diets is limited by study design flaws, including hetero geneity of patient populations, absence of standardized outcome measures, high dropout rates and, in some studies, nonblinded raters.

Although research findings are mixed, sugar has long been suspected as an underlying causative factor in ADHD. In a 9-week placebo-controlled study, children without ADHD who were randomized to diets high in sucrose, aspartame, or saccharin showed no differences in behavior.12 The expectations of parents may bias the perceptions of their children's behavior following the consumption of large quantities of sugar. In one controlled trial, mothers who believed their child had eaten sugar were more likely to label their child's behavior as hyperactive.13

In their comprehensive review of nonpharmacological therapies for ADHD, Weber and Newmark¹⁴ remarked that the study design did not adequately control for fruits, juices, or other dietary sources of sugar and suggested that future studies should not focus primarily on sugar but rather on a possible link between highglycemic-index foods and hyperactivity. Large prospective controlled studies on dietary restrictions as therapeutic interventions in ADHD have been elusive because of difficulties in controlling eating behavior in both children and adults.15

EEG biofeedback. Children and adults with ADHD often have abnormal patterns of brain electrical activity; underarousal in frontal and midline cortical regions is found in up to 90% of cases, and frontal hyperarousal is especially noted in individuals who have not responded to stimulants.16 Electroencephalographic (EEG) biofeedback is aimed at normalizing EEG activity by correcting the brain's state of relative underarousal, thereby optimizing cognitive and behavioral functioning.17

Two EEG biofeedback protocols have been extensively studied as treatments of ADHD. With sensorimotor rhythm (SMR) training, the goal is to reinforce EEG activity in the faster beta frequency range (16 to 20 Hz) in the midline cortical regions, and it is targeted at reducing symptoms of impulsivity and hyperactivity. In contrast, theta suppression aims to reduce EEG activity in the slower theta frequency range (4 to 8 Hz) and is used primarily to treat symptoms of inatt ention.

Controlled studies that compared EEG biofeedback to a stimulant medication with a wait list report consistent beneficial clinical effects and EEG normalization with SMR and theta suppression EEG biofeedback protocols.18,19 However, causal rela-

by James Lake, MD

tionships between improvements in attention and increased or decreased alpha activity (12 to 18 Hz) have not been clearly established. The signif-



icance of most findings on EEG biofeedback is limited by study design flaws that include small study sizes, heterogeneous populations, absence of a control (ie, sham biofeedback) group, inconsistent outcome measures, self-selection bias (the majority of enrolled subjects were highly motivated to receive treatment), and limited or no long-term followup.

Natural products used to treat ADHD. The finding that children with ADHD have lower plasma concentrations of certain essential fatty acids (EFAs) than those in a healthy population has led to the hypothesis that fatty acid deficiencies during critical developmental phases increase the risk of acquiring ADHD.^{20,21} Few controlled studies have examined the effect of EFAs in children with ADHD, and findings are inconsistent.

One study on EFAs as an adjunctive therapy to stimulant medications found no differential benefit of EFAs compared with stimulants plus a placebo.22 Another adjunctive study found only modest improvements over placebo in disruptive behavior and attention.23

In a placebo-controlled trial on EFAs as a stand-alone treatment of ADHD, parents of children in the treatment group reported more improvement than did parents of children receiving a palm oil placebo.²⁴ This study has been criticized because a high dropout rate biases findings in a positive direction.¹⁴ The use of olive oil as a placebo may mask the beneficial clinical effects of EFAs because an active constituent of olive oil is converted into oleamide, which is known to affect brain function.25 It has also been suggested that the relatively short durations and low doses of EFAs used in these studies may not be adequate to result in changes in neuronal membrane structure required for clinical improvement.22

The issue of dosing has been addressed by a small open-label study (N = 9) in which children with ADHD were given supplemental

JULY 2010

INTEGRATIVE MEDICINE

high-dose eicosapentaenoic acid/ docosahexaenoic acid (EPA/DHA) concentrates (16.2 g/d) while they continued to take stimulant medications. Most children were rated by a blinded psychiatrist as having significant improvements in both inattention and hyperactivity that correlated with reductions in the arachidonic acid to EPA ratio at the end of an 8-week treatment.²⁶ Large prospective

trials in different age-groups are needed to replicate these findings before omega-3s can be generally recommended for ADHD.

Herbal preparations

In a 4-week study, 36 children with ADHD were randomized to an herbal preparation containing *Ginkgo biloba* and *Panax quinquefolius* (American ginseng) or to a combination of the herbal preparation and stimulant medication.²⁷ Beneficial effects in attention and impulsivity were observed in children taking the herbal preparation alone; however, the absence of a comparison group (ie, taking a stimulant only) and small study size limit the significance of the findings.

Findings of several open studies suggest that a standardized extract of

Pinus pinaster (French maritime pine) bark is an effective treatment of ADHD, although to date, only 1 double-blind placebo-controlled trial has been published.²⁸ Children and adolescents randomized to a standardized extract of French maritime pine bark (Pycnogenol, 1 mg/kg/d for 1 month) experienced significant improvements in hyperactivity, inattention,

PSYCHIATRIC TIMES

www.psychiatrictimes.com

(Please see ADHD, page 10)

9

Table Nonconventional and integrative treatments of ADHD48		
Research methods	Significant findings	Comments
Double-blind placebo-controlled challenge cross-over trial (N = 300, ADHD children), phase 1 elimination, phase 2 challenge ⁴⁹ ; double-blind placebo-controlled challenge cross-over trial, phase 1 open elimination followed by challenge (N = 56, 4 - 12 y with behavioral problems) ⁵⁰	75% improved with restricted diet, however symptoms recurred when food colorings and additives reintroduced; improved behavior and attention scores	No description of recruitment or eligibility of nonresponders in phase 2; more restrictive than Feingold but less restrictive than OAD protocol
1-y clinical trial stimulants vs EEG biofeedback + stimulants (N = 100, 6 - 19 y) ¹⁷ ; 12-wk clinical trial EEG biofeedback SMR and beta rhythms 3/wk or stimulants (N = 34, 8 - 12 y) ⁵¹	Symptoms improved with stimulants but only biofeedback group sustained improvement without stimulants at 1-y follow-up; Conners scores significantly improved in EEG biofeedback group	Group assignments based on parental preference; average of 43 sessions required for sustained improvement
4-wk RCT (N = 34, ADHD children) randomized to <i>Ginkgo biloba</i> + American ginseng or ongoing stimulant medication + herbals; 1-mo RCT (N = 61) standardized extract of French maritime pine bark (1 mg/kg/d) ²⁹ ; RCT (N = 85, healthy men and women) extract of <i>Ginkgo biloba</i> and <i>Bacopa monnieri</i> or placebo ³⁰	No improvements in ADHD symptoms; significant improvements in hyperactivity, inattention, and visual-motor coordination; no improvements over placebo in short-term memory, working memory, executive processing, etc	No comparison group treated with stimulants only; large studies needed to replicate findings; study population consisted of normal individuals; large prospective dose-finding trials on ADHD patients needed
12-wk RCT (N = 400, children and adolescents) high-dose zinc (150 mg/d) or placebo ³³ ; 12-wk RCT non-anemic ADHD children with low serum ferritin levels treated with oral iron (80 mg/d) or placebo ⁵²	Significant improvement in hyperactivity and impulsivity but not inattention; improvements with iron comparable to those with stimulants	High dropout rate limits significance; large prospective studies needed to confirm efficacy and determine optimal dosing
2-mo double-blind placebo-controlled randomized trial (N = 40, 6 - 12 y), diet consisted of DHA-enriched foods or olive oil–enriched foods ⁵³ ; 8-wk open pilot study (N = 9) children given high-dose EPA/DHA concentrates (16.2 g/d) then rated by blinded psychiatrist; 16-wk pilot study (N = 112, ADHD children) randomized to ALC (500 - 1500 mg bid) or placebo	Short-term memory improved in control group but not DHA group; no differences in parent or teacher ratings of behavior or cognition; significant improvements in behavior and inattention correlated with reduced AA to EPA ratio and global severity of illness scores; no serious adverse effects reported	Olive oil may not be inert; some subjects had comorbid Asperger, conduct, learning, and mood disorders; no placebo group; some subjects had comorbid conduct disorder or oppositional-defiant disorder (which also improved during study); dietary intake not recorded at baseline or during study; supplement intake not closely monitored
	ALC superior to placebo in inattentive- type ADHD but not combined-type ADHD	Large prospective trials needed
In 2 small controlled studies, ADHD children stable while receiving medica- tions were randomized to yoga or regular massage therapy ^{45,46}	Trend toward reducing severity of ADHD symptoms with regular yoga and massage	Possible group expectation effects; large prospective studies needed
	Nonconventional and i Research methods Double-blind placebo-controlled challenge cross-over trial (N = 300, ADHD children), phase 1 elimination, phase 2 challenge ⁴⁹ ; double-blind placebo-controlled challenge cross-over trial, phase 1 open elimination followed by challenge (N = 56, 4 - 12 y with behavioral problems) ⁵⁰ 1-y clinical trial stimulants vs EEG biofeedback + stimulants (N = 100, 6 - 19 y) ¹⁷ ; 12-wk clinical trial EEG biofeedback SMR and beta rhythms 3/wk or stimulants (N = 34, 8 - 12 y) ⁵¹ 4-wk RCT (N = 34, ADHD children) randomized to <i>Ginkgo biloba</i> + American ginseng or ongoing stimulant medication + herbals; 1-mo RCT (N = 61) standardized extract of French maritime pine bark (1 mg/kg/d) ²⁹ ; RCT (N = 85, healthy men and women) extract of <i>Ginkgo biloba</i> and <i>Bacopa monnieri</i> or placebo ³⁰ 12-wk RCT (N = 400, children and adolescents) high-dose zinc (150 mg/d) or placebo ³⁰ 12-wk RCT (N = 400, children and adolescents) high-dose zinc (150 mg/d) or placebo ³⁰ 1	Nonconventional and integrative treatments of AResearch methodsSignificant findingsDouble-blind placebo-controlled challenge cross-over trial (N = 300, ADH0 children), phase 1 elimination, phase 2 challenge**, double-blind placebo-controlled challenge cross-over trial, phase 1 open elimination followed by challenge (N = 56, 4 - 12 y with behavioral problems)***75%, improved with restricted diet, however symptoms recurred when food colorings and additives reintroduced; improved behavior and attention scores1-y clinical trial stimulants ve EEG biofeedback + stimulants (N = 100, 6 - 19 y)*; 12-wk clinical trial EEG biofeedback SMR and beta rhythms 3/wk or stimulants (N = 34, 8 - 12 y)**Symptoms improved with stimulants but only biofeedback group sustained improvement without stimulants at 1-y follow-up; Conners scores significant improvements in ADHD symptoms; significant improvements over (N = 61) standardized extract of French maritime pine bark (1 mg/kg/d)*; RCT (N = 85, healthy men and women) extract or placebo**No improvements in ADHD symptoms; significant improvements over placebo in short-term memory, working memory, executive processing, etc12-wk RCT (N = 400, children and adolescents) high-dose zinc (150 mg/d) or placebo**Significant improvement in hyperactivity and impulsivity but not inattention; improved in control group but not DHA group; no differences in parent or teacher ratings of behavior or cognition; significant improvements in behavior and inattention correlated with reduced Ato EPA ratio and global severity or placebo**12-wk RCT (N = 40, 6 - 12 y), diet consisted of DHA-enriched foods or glivo oil-enriched foods**; 8-wk open pilot study (N = 9) children gliven high-dose pilot study (N =

ADHD, attention-deficit/hyperactivity disorder; OAD, oligoantigenic diet; EEG, electroencephalographic; SMR, sensorimotor rhythm; RCT, randomized clinical trial; EFAs, essential fatty acids; DHA, docosahexaenoic acid; EPA, eicosapentanoic acid; ALC, acetyl-L-carnitine; AA, arachidonic acid.



INTEGRATIVE MEDICINE

ADHD Continued from page 9

and visual-motor coordination over those receiving placebo; however, symptoms returned to pretreatment baseline levels after a 1-month washout.²⁸ One case of mild gastric discomfort was reported, and there were no serious adverse effects. Well-designed controlled studies are needed to replicate these preliminary findings.

Bacopa monnieri (Brahmi) is an Ayurvedic medicinal herbal preparation that is widely used as a tonic and memory enhancer. In a small, 12week double-blind randomized clinical trial (RCT), 36 children who had ADHD and who were randomized to bacopa 50 mg twice a day showed significant improvement over those receiving placebo in tests of sentence repetition, logical memory, and pairassociative learning.²⁹ Large placebocontrolled trials are needed to confirm the safety and efficacy of bacopa as a treatment of ADHD.

Supplementation with trace elements

Zinc. Children who have ADHD frequently have abnormally low plasma zinc levels, which may interfere with optimal information processing and correlate with the severity of inattentive symptoms.^{30,31} Zinc supplementation is a widely used alternative treatment of ADHD; nevertheless, few studies have been done and findings are inconsistent. In a large 12-week double-blind placebo-controlled trial (N = 400), children and adolescents who were randomized to a high dose of zinc (150 mg/d) experienced significant improvement in hyperactivity and impulsivity but not inattention over those receiving placebo.³² A high dropout rate limits the significance of these findings.

In another study, the addition of zinc to methylphenidate therapy resulted in greater improvement than methylphenidate alone.³³ Large prospective studies are needed to replicate these preliminary findings and to confirm optimum dosing of zinc sulfate.³⁴

Iron. The incidence of iron deficiency as measured by serum ferritin levels may be higher in children with ADHD than in a matched population of children without ADHD.³⁵ Abnormally low serum ferritin levels may be associated with relatively greater hyperactivity in non-anemic children with ADHD but not with differences in cognitive performance tasks.³⁶ In an open trial, non-iron-deficient children given oral iron for 1 month

were perceived as less hyperactive and distractible by teachers—but not by parents.³⁷

In a small, 12-week placebo-controlled trial, non-anemic children with ADHD who had abnormally low serum ferritin levels were randomized to oral iron (ferrous sulfate, 80 mg/d). Progressive improvements in the severity of ADHD symptoms were observed relative to placebo throughout the study: the effect was comparable to clinical improvements obtained with stimulants.³⁵ Large controlled studies are needed to confirm putative beneficial effects of iron supplementation in ADHD and to determine optimal dosing.

Acetyl-L-carnitine is required for energy metabolism and synthesis of fatty acids. Findings from a small study suggest that acetyl-L-carnitine significantly reduces the severity of ADHD symptoms. However, study design flaws, including failure to report pretreatment and posttreatment symptoms, limit the significance of beneficial effects of homeopathy on symptom severity, core symptoms, or the course of ADHD.⁴¹

Frei and colleagues⁴² have pointed out that conventional RCT study designs may interfere with the goal of demonstrating clinically relevant treatment effects of specific homeopathic remedies for ADHD. They suggest that long-term studies are needed that incorporate an initial open-label phase to identify the optimal treatment for each patient who can then be randomized to his or her optimum remedy or to a randomly selected homeopathic preparation in a subsequent placebo-controlled phase.

Yoga and massage

In a small pilot study, children with ADHD randomized to yoga experienced more significant reductions in symptoms over time than children assigned to a conventional exercise group. Children who continued to take stimulants while practicing yoga

As many as 80% of patients who use herbal preparations and other natural products regard these therapies as the primary treatment of their [ADHD] symptoms.

the findings.³⁸ In a multisite, 16-week pilot study, 112 children with ADHD, aged 5 to 12 years, were randomized to placebo or to acetyl-L-carnitine (500 to 1500 mg bid).³⁹ The Conners parent and teacher rating scales administered at baseline, and at 8, 12, and 16 weeks showed the superiority of acetyl-L-carnitine over placebo in inattentive-type children; however, there was no improvement over placebo in combined-type children. Significant adverse effects were not reported. Future studies are warranted to examine specific therapeutic effects of acetyl-L-carnitine in the inattentive type of ADHD. Findings of a small randomized placebo-controlled study suggest that acetyl-L-carnitine given in doses of 50 mg/kg/d improves symptoms of hyperactivity in young boys with fragile X syndrome and ADHD.40

Homeopathic remedies

Homeopathic remedies are widely used in the United States and other countries to treat or self-treat ADHD. A recent systematic review of RCTs on homeopathic treatments in ADHD concluded that there is no evidence of experienced the greatest improvements.⁴³ Two small controlled studies suggest that yoga and regular massage therapy may reduce the severity of ADHD symptoms.^{44,45} Large prospective studies are needed to confirm beneficial effects and test for possible group expectation effects of yoga and massage in ADHD.

Green play environments

A recently proposed theory conceptualizes ADHD as the result of attention fatigue caused by limited contact with green spaces during early childhood development. Findings of a large observational study suggest that children with ADHD who spend more time playing outdoors in natural environments may experience fewer and less severe symptoms of ADHD.⁴⁶ These findings have been criticized because of design flaws, including a highly heterogeneous population that included children with severe symptoms or comorbid oppositional-defiant disorder, absence of independent raters, absence of a comparison group, and reliance on the impressions of parents using nonstandardized rating scales.47

Summary of key findings

To be most effective, the integrative management of ADHD should be individualized, taking into account the specific causes of the syndrome in each patient, including genetic factors, perinatal insults or toxic exposure, food sensitivities, and social factors. Stimulant and nonstimulant medications are often beneficial and are well tolerated for a significant percentage of children, adolescents, and adults with ADHD. When stimulants are ineffective, poorly tolerated, or refused by the patient (or the patient's parents), validated EEG biofeedback protocols-including SMR training for primarily hyperactive-type ADHD and theta suppression for primarily inattentive-type ADHD—are reasonable alternatives.

The Table summarizes significant research findings for the nonconventional and integrative therapies for ADHD discussed in this article. Dietary restrictions on food colorings and additives or on foods that may be causing allergic reactions may significantly reduce symptoms of hyperactivity in some cases. Zinc supplementation may be helpful in cases when hyperactivity and impulsive behavior do not respond to stimulants alone. Emerging findings suggest that supplementation with iron and acetyl-L-carnitine may reduce symptoms of distractibility and inattention in some cases of ADHD. Large prospective placebo-controlled studies are needed before zinc, iron, or acetyl-L-carnitine can be generally recommended for the treatment of ADHD. High doses of omega-3 EFAs (up to 16 g/d) may have beneficial effects on symptoms of both inattention and hyperactivity. More studies are needed to determine the optimal form and dosing of omega-3s in children and adults in whom ADHD is diagnosed. Extracts of Ginkgo biloba, Panax quinquefolius, Pinus pinaster, and Bacopa monnieri may be beneficial; however, conclusive findings from large prospective controlled trials are needed before any of these herbal preparations can be recommended as adjunctive or first-line treatments.

Dr Lake is in private practice in Monterey, Calif, and is on the clinical faculty in the department of psychiatry and behavioral sciences at Stanford University Hospital. He chairs the American Psychiatric Association Caucus on Complementary, Alternative, and Integrative Medicine (www.APACAM.org) and is the author of the Textbook of Integrative Mental Health Care (Thieme, 2006) and Integrative Mental Health: A Therapist's Handbook (Norton, 2009).

JULY 2010

INTEGRATIVE MEDICINE-

11 **PSYCHIATRIC TIMES**

www.psychiatrictimes.com

References

1. Bussing B. Zima BT. Gary FA. Garvan CW. Use of complementary and alternative medicine for symptoms of attention-deficit hyperactivity disorder. Psychiatr Serv. 2002:53:1096-1102

2. Chan E, Rappaport LA, Kemper KJ. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr. 2003; 24:4-8

3. Findling RL. Evolution of the treatment of attentiondeficit/hyperactivity disorder in children: a review. Clin Ther. 2008;30:942-957

4. Newcorn JH, Weiss M, Stein MA. The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. CNS Spectr. 2007;12(8, suppl 12):1-14.

5. Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165: 1475-1488

6. Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. 2009;14:123-142.

7. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? J Clin Psychiatry. 2003;64(suppl 11):9-13.

8. Upadhyaya HP. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry. 2007;68(suppl 11):23-30. 9. Feingold B. Why Your Child Is Hyperactive. New York: Random House; 1975.

10. Wender EH. The food additive-free diet in the treatment of behavior disorders: a review. J Dev Behav Pediatr. 1986;7:35-42.

11. Rojas NL, Chan E. Old and new controversies in the alternative treatment of attention-deficit hyperactivity disorder. Ment Retard Dev Disabil Res Rev. 2005;11:116-130.

12. Wolraich ML, Lindgren SD, Stumbo PJ, et al. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. N Engl J Med. 1994;330:301-307.

13. Hoover DW, Milich R. Effects of sugar ingestion expectancies on mother-child interactions. J Abnorm Child Psychol. 1994;22:501-515.

14. Weber W, Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am. 2007;54:983-1006.

15. Cormier E. Elder JH. Diet and child behavior problems: fact or fiction? Pediatr Nurs. 2007;33:138-143. 16. Butnik SM. Neurofeedback in adolescents and adults with attention deficit hyperactivity disorder. J Clin Psychol, 2005:61:621-625.

17. Monastra VJ, Monastra DM, George S. The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attentiondeficit/hyperactivity disorder. Appl Psychophysiol Biofeedback. 2002;27:231-249.

18. Monastra VJ, Lynn S, Linden M, et al. Electroencephalographic biofeedback in the treatment of attention-deficit/hyperactivity disorder. Appl Psychophysiol Biofeedback. 2005;30:95-114

19. Ramirez PM, Desantis D, Opler LA. EEG biofeedback treatment of ADD: a viable alternative to traditional medical intervention? Ann N Y Acad Sci. 2001:931:342-358.

20. Bekaroglu M, Aslan Y, Gedik Y, et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry. 1996;37:225-227.

21. Richardson AJ, Puri BK. The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2000;63:79-87. 22. Voigt RG, Llorente AM, Jensen CL, et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr. 2001:139:189-196.

23. Stevens LJ, Zentall SS, Deck J, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr. 1995;62:761-768. 24. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr. 2007;28:82-91.

25. Richardson AJ, Puri BK, A randomized doubleblind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:233-239.

26. Sorgi PJ, Hallowell EM, Hutchins HL, Sears B. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J. 2007:6:16. http://www.nutritioni. com/content/pdf/1475-2891-6-16.pdf. Accessed April 29, 2010.

27. Lyon MR, Cline JC, Totosy de Zepetnek J, et al. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study. J Psychiatry Neurosci. 2001;26:221-228

28. Trebatická J, Kopasová S, Hradecná Z, et al. Treatment of ADHD with French maritime pine bark extract:

Pycnogenol. Eur Child Adolesc Psychiatry. 2006;15: 329-335.

29. Nathan PJ, Tanner S, Lloyd J, et al. Effects of a combined extract of Ginkgo biloba and Bacopa monnieri on cognitive function in healthy humans. Hum Psychopharmacol. 2004;19:91-96

30. Yorbik O, Ozdag MF, Olgun A, et al. Potential effects of zinc on information processing in boys with attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:662-667.

31. Arnold LE. Bozzolo H. Hollway J, et al. Serum zinc correlates with parent- and teacher-rated inattention in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15:628-636

32. Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28: 181-190.

33. Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry. 2004;4:9.

34. Arnold LE, DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15:619-627.

35. Konofal E, Lecendreux M, Arnulf I, Mouren MC. Iron deficiency in children with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 2004:158:1113-1115.

with symptom ratings and cognitive performance in children with attention deficit-hyperactivity disorder.

37. Sever Y, Ashkenazi A, Tyano S, Weizman A. Iron treatment in children with attention deficit hyperactivity disorder: a preliminary report. Neuropsychobiol-

nitine in the treatment of children with attentiondeficit hyperactivity disorder. Prostaglandins Leukot

nitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site. placebo-controlled pilot trial. J Child Ado-

40. Torrioli MG, Vernacotola S, Peruzzi L, et al. A double-blind, parallel, multicenter comparison of Lacetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008:146:803-812.

deficit/hyperactivity disorder or hyperkinetic disorder.

Cochrane Database Syst Rev. 2007;(4):CD005648. 42. Frei H. Everts R. von Ammon K. et al. Randomised controlled trials of homeopathy in hyperactive children: treatment procedure leads to an unconventional study design. Experience with open-label homeopathic treatment preceding the Swiss ADHD placebo controlled, randomised, double-blind, cross-over trial. Homeopathy. 2007;96:35-41.

43. Haffner J, Roos J, Goldstein N, et al. The effectiveness of body-oriented methods of therapy in the treatment of attention-deficit hyperactivity disorder (ADHD): results of a controlled pilot study [in German]. Z Kinder Jugendpsychiatr Psychother. 2006;34: 37-47.

44. Jensen PS, Kenny DT. The effects of yoga on the attention and behavior of boys with attention-deficit/ hyperactivity disorder (ADHD). J Atten Disord. 2004; 7:205-216.

45. Khilnani S, Field T, Hernandez-Reif M, Schanberg S. Massage therapy improves mood and behavior of students with attention-deficit/hyperactivity disorder. Adolescence, 2003:38:623-638.

46. Kuo FE, Taylor AF. A potential natural treatment for attention-deficit/hyperactivity disorder: evidence from a national study. Am J Public Health. 2004;94: 1580-1586

47. Canu W, Gordon M. Mother nature as treatment for ADHD: overstating the benefits of green. Am J Clin Health. 2005;95:371.

48. Lake J. Attention-deficit and hyperactivity disorder (ADHD). In: Sarris J, Wardle J, eds. Clinical Naturopathy: An Evidence-Based Guide to Practice. Sydney: Elsevier Australia; 2010:693-706

49. Rowe KS, Rowe KJ. Synthetic food coloring and behavior: a dose response effect in a double-blind. placebo-controlled, repeated-measures study. J Pediatr. 1994;125(5, pt 1):691-698.

50. Dengate S. Ruben A. Controlled trial of cumulative behavioural effects of a common bread preservative. J Paediatr Child Health, 2002:38:373-376.

51. Fuchs T, Birbaumer N, Lutzenberger W, et al. Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: a comparison with methylphenidate. Appl Psychophysiol Biofeedback. 2003; 28:1-12.

52. Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol. 2008; 38:20-26

53. Hamazaki T, Hirayama S. The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder: a placebo-controlled double-blind study. Eur J Clin Nutr. 2004;58:838.

CRUSH YOUR PSYCHIATRY BOARD EXAM

If you have a psychiatry board exam coming up anytime soon, you have two choices. You can face the exam alone, or you can take a course that guarantees your success — that's exactly what the Beat The Boards!® Courses do!

At the **Beat The Boards!** courses, you focus only on the knowledge and skills you need to ace your board exam. With the outrageous quarantees we offer, there is no reason for

you to face your exam anxious and unprepared. So why not join us? Thousands have!

QKg Dr. Jack Krasuski, MD Executive Director

AMERICAN

Upcoming Course Schedule:

Psychiatry Part 1 (Written) Course Chicago, IL 03/17 - 03/21/2011

Psychiatry Certification Course Chicago, IL 07/28 - 08/01/2011

-		
Psychiatry Part 2 (Oral) Course		
Chicago, IL	08/12 - 08/15/2010	

Chicago, IL 09/27 - 09/30/2010 Pittsburgh, PA Chicago, IL 12/02 - 12/05/2010 Los Angeles, CA 01/10 - 01/13/2011 05/30 - 06/02/2011 Portland, OR Home Study Version Available Now

Psychiatry MOC Course

Los Angeles, CA 01/07 – 01/09/2011 Home Study Version Available Now

Child & Adolescent Psychiatry Part 2 (Oral) Course 10/14 - 10/17/2010 Chicago, IL Austin, TX 11/15 - 11/18/2010

"The course was simply the best imaginable. How I wish I could have learnt these skills when I was a resident. I firmly believe I've learnt not only to prepare for the exam but to be a better doctor and psychiatrist. Keep it up." Jose Matthews, MD, Chicago, IL — 2010 Psychiatry Part 2 (Oral) Course Attendee

Visit Us at BeatTheBoards.com to Read Hundreds More Testimonials

Call Now to Secure Your Place — And Your Future! 877-225-8384 or register online at BeatTheBoards.com

Ace your board exam by joining the nation's #1 psychiatry board prep courses. *Course info tion is subject to chang

PHYSICIAN INSTITUTE MERICAN FORADVANCED PROFESSIONAL STUDIES

ogy. 1997;35:178-180.

Essent Fatty Acids. 2002;67:33-38. 39. Arnold LE, Amato A, Bozzolo H, et al. Acetyl-L-car-

lesc Psychopharmacol. 2007;17:791-802.

41. Coulter MK, Dean ME. Homeopathy for attention

36. Oner O, Alkar OY, Oner P. Relation of ferritin levels

Pediatr Int. 2008;50:40-44.

38. Van Oudheusden L.L. Scholte HR. Efficacy of car-

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.